Cue Biopharma (CUE) is scheduled to provide a quarterly update after the bell today (details here).

It’s possible the company will use it as a venue to provide the highly anticipated interim data on CUE-101 for the treatment of HPV-driven cancers.

Personally, I believe the company would maximize visibility and impact by revealing the data in a few weeks at the ASCO conference instead.

Regardless of where and when it’s revealed, all the evidence points to it being overwhelmingly positive.

Now, by saying that I realize it makes CUE sound like a sure thing. We know sure things don’t exist in the markets, particularly biotechs. But the evidence hiding in plain sight substantiates my strong conviction.


Want to keep reading? No problem! All you have to do is sign up for FREE here as a registered user. 

By doing so, you agree to receive periodic research updates from DTR and only DTR.

We will never rent, sell or share your info.